FDA expands Ozempic label to include kidney disease benefits in type 2 diabetes patients. Novo Nordisk's drug can now be ...

Novo Nordisk is asking a federal appeals court to make haste on its case challenging the Inflation Reduction Act's drug ...

KFF analysis highlights that ACA marketplace insurers denied 19% of claims. Less than 1% of denials were appealed, and ...

Robert F. Kennedy Jr. will sit before a Senate committee on Wednesday and provide the first substantive glimpse into how he ...

Another obesity biotech emerged on Tuesday morning, this time taking a different approach to the GIP antagonism story than ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

ITM-11 beats everolimus in Phase 3 GEP-NETs trial; ITM plans filing. Drug will compete with Novartis's Lutathera. Both use ...

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News.

Leap Therapeutics reported mixed results on Tuesday for an experimental treatment in gastric and colorectal cancer, announcing it is only moving forward with the latter indication. The biotech’s ...

In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and ...

For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering ...

Affini-T Therapeutics appears to have cut staff last week, according to LinkedIn posts from people who say they are or were ...